North Texas Clinical Trials

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Depression7 trials
• Alzheimer disease2 trials
• Insomnia2 trials
• Autism1 trial
• Bipolar disorder1 trial
• Schizophrenia1 trial

Phase

• Phase 37 trials
• Phase 23 trials

Status

• Completed7 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Cognito Therapeutics, Inc.2 trials
• Boehringer Ingelheim1 trial
• COMPASS Pathways1 trial
• Cybin IRL Limited1 trial
• and 4 more

Running trials

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Cognito Therapeutics, Inc.· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Autism1 recruiting
• Depression1 recruiting
• Insomnia1 recruiting

Closed trials

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Cybin IRL Limited· Source

  Contact: Clinical Development

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Cognito Therapeutics, Inc.· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Denovo Biopharma LLC· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Janssen Research & Development, LLC· Source